Skip to main content

Table 1 Post-stratification variables

From: Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes

 

EMPA-REG

TECOS

SAVOR-TIMI

SUSTAIN-6

LEADER

EXSCEL

REWIND

PIONEER-6

DECLARE

Duration of diabetes

 

X

X

X

X

X

X

 

X

Age

X

X

X

X

X

X

X

X

X

Sex

X

X

X

X

X

X

X

X

 

HbA1c

X

X

X

X

X

X

X

X

 

BMI

X

X

X

X

X

X

X

X

 

Body weight

  

X

      

Systolic blood pressure

X

X

       

Diastolic blood pressure

X

X

       

Established CVD

X

  

X

X

X

X

X

 

Prior MI or Stroke

X

  

X

  

X

X

 

PAD

X

        

Previous MI

X

       

X

Heart failure

 

X

X

X

X

X

  

X

CVD risk factors

X

  

X

X

  

X

X

Only cerebrovascular disease

X

        

eGFR

X

X

 

X

X

X

 

X

X

Urinary albumin/creatinine ratio

X

 

X

      

Anti-diabetic therapy

    

X

    

Insulin

X

X

X

X

 

X

   

Metfromin

X

X

X

      

Sulphonylurea

X

X

X

      

Thiazolidinediones

X

X

X

      

DPP-4i

X

    

X

   

Anti-hypertive therapy

X

 

X

      

RAS blockers

 

X

X

      

Calcium channel blockers

X

X

       

Beta blockers

X

X

       

Diuretics

X

X

X

      

Aspirin

X

        

Statin

X

X

X

      

Europe

X

X

X

X

X

X

X

  

Ethnicity

X

  

X

X

    

White

X

X

X

X

X

X

X

X

 

Number of variables

28

20

18

14

13

12

9

9

6

  1. For each cardiovascular outcome trial, we report which variables were used for post-stratification transposition to the target population
  2. BMI body mass index, CVD cardiovascular disease, PAD peripheral arterial disease, MI myocardial infarction, eGFR estimated glomerular filtration rate, DPP-4 dipeptidyl peptidase-4, RAS renin angiotensin system